Overexpression of endothelin-1 and endothelin receptors in the pulmonary arteries of failed Fontan patients

International Journal of Cardiology

Volumn 159, Issue 1, 2012, Pages 34-39

  Ishida, Hidekazu ^a   Kogaki, Shigetoyo ^a   Ichimori, Hiroaki ^a   Narita, Jun ^a   Nawa, Nobutoshi ^a   Ueno, Takayoshi ^a   Takahashi, Kunihiko ^b   Kayatani, Futoshi ^b   Kishimoto, Hidehumi ^b   Nakayama, Masahiro ^b   Sawa, Yoshiki ^a   Beghetti, Maurice ^c   Ozono, Keiichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Endothelin receptor; Endothelin 1; Fontan procedure; Immunohistochemistry

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; MESSENGER RNA;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; FEMALE; FONTAN PROCEDURE; GENE EXPRESSION; HEART FAILURE; HEART HYPERTROPHY; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG PARENCHYMA; LUNG VASOCONSTRICTION; MALE; OPTICAL DENSITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY VASCULAR DISEASE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; SURGICAL MORTALITY; TREATMENT FAILURE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; ENDOTHELIN-1; FEMALE; FOLLOW-UP STUDIES; FONTAN PROCEDURE; GENE EXPRESSION REGULATION; HUMANS; MALE; PULMONARY ARTERY; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; TREATMENT FAILURE;

EID: 84863781799     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.02.021     Document Type: Article

References (25)

1. Tweddell JS, Nersesian M, Mussatto KA, Nugent M, Simpson P, Mitchell ME, et al. Fontan palliation in the modern era: factors impacting mortality and morbidity. Ann Thorac Surg 2009;88:1291-9.
2. Driscoll DJ. Long-term results of the Fontan operation. Pediatr Cardiol 2007;28: 438-42. (Pubitemid 350160288)
3. Mair DD, Puga FJ, Danielson GK. The Fontan procedure for tricuspid atresia: early and late results of a 25-year experience with 216 patients. J Am Coll Cardiol 2001;37:933-9. (Pubitemid 32202466)
4. Khairy P, Fernandes SM, Mayer JE Jr, Triedman JK, Walsh EP, Lock JE, et al. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation 2008;117:85-92. (Pubitemid 350291185)
5. Giglia TM, Humpl T. Preoperative pulmonary hemodynamics and assessment of operability: is there a pulmonary vascular resistance that precludes cardiac operation? Pediatr Crit Care Med 2010;11:S57-69.
6. Hosein RB, Clarke AJ, McGuirk SP, Griselli M, Stumper O, De Giovanni JV, et al. Factors influencing early and late outcome following the Fontan procedure in the current era. Eur J Cardiothorac Surg 2007;31:344-52 discussion.
7. Levy M, Danel C, Tamisier D, Vouhe P, Leca F. Histomorphometric analysis of pulmonary vessels in single ventricle for better selection of patients for the Fontan operation. J Thorac Cardiovasc Surg 2002;123:263-70. (Pubitemid 34127113)
8. Maeda K, Yamaki S, Kado H, Asou T, Murakami A, Takamoto S. Reevaluation of histomorphometric analysis of lung tissue in decision making for better patient selection for Fontan-type operations. Ann Thorac Surg 2004;78:1371-81 discussi.
9. Hiramatsu T, Imai Y, Takanashi Y, Seo K, Terada M, Aoki M, et al. Time course of endothelin-1 and adrenomedullin after the Fontan procedure. Ann Thorac Surg 1999;68:169-72. (Pubitemid 29338984)
10. Yamagishi M, Kurosawa H, Hashimoto K, Nomura K, Kitamura N, et al. The role of plasma endothelin in the Fontan circulation. J Cardiovasc Surg Torino 2002;43: 793-7. (Pubitemid 36040810)
11. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001;120:1562-9. (Pubitemid 33078473)
12. Levy M, Danel C, Laval AM, Leca F, Vouhe PR, Israel Biet D. Nitric oxide synthase expression by pulmonary arteries: a predictive marker of Fontan procedure outcome? J Thorac Cardiovasc Surg 2003;125:1083-90. (Pubitemid 36644886)
13. Davie N, Haleen SJ, Upton PD, Polak JM, Yacoub MH, Morrell NW, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002;165:398-405. (Pubitemid 34118516)
14. Gregan B, Schaefer M, Rosenthal W, Oksche A. Fluorescence resonance energy transfer analysis reveals the existence of endothelin-A and endothelin-B receptor homodimers. J Cardiovasc Pharmacol 2004;44(Suppl 1):S30-3. (Pubitemid 40039638)
15. Black SM, Mata Greenwood E, Dettman RW, et al. Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow. Circulation 2003;108:1646-54. (Pubitemid 37187794)
16. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23. (Pubitemid 32971843)
17. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. (Pubitemid 34984638)
18. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-9.
19. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169: 441-7. (Pubitemid 38187114)
20. Apostolopoulou SC, Papagiannis J, Rammos S. Bosentan induces clinical, exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation. J Heart Lung Transplant 2005;24:1174-6. (Pubitemid 41127216)
21. Ovaert C, Thijs D, Dewolf D, Ottenkamp J, Dessy H, Moons P, et al. The effect of bosentan in patients with a failing Fontan circulation. Cardiol Young 2009;11: 1-9.
22. Reinhardt Z, Uzun O, Bhole V, Ofoe V, Wilson D, Onuzo O, et al. Sildenafil in the management of the failing Fontan circulation. Cardiol Young 2010;20:1-4.
23. Beghetti M. Fontan and the pulmonary circulation: a potential role for new pulmonary hypertension therapies. Heart 2010;96:911-6.
24. Hirono K, Yoshimura N, Taguchi M, et al. Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery. J Thorac Cardiovasc Surg Apr. 2010;140:28.
25. Shewan LG and Coats AJ. Ethics in the authorship and publishing of scientific articles. Int J Cardiol 2010;144:1-2.